These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 8397580)

  • 21. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
    Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.
    Nolan T; Lambert S; Roberton D; Marshall H; Richmond P; Streeton C; Poolman J; Boutriau D
    Vaccine; 2007 Dec; 25(51):8487-99. PubMed ID: 17996996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults.
    Aguilar-Betancourt A; González-Delgado CA; Cinza-Estévez Z; Martínez-Cabrera J; Véliz-Ríos G; Alemán-Zaldívar R; Alonso-Martínez MI; Lago-Baños M; Puble-Alvarez N; Delahanty-Fernandez A; Juvier-Madrazo AI; Ortega-León D; Olivera-Ruano L; Correa-Fernández A; Abreu-Reyes D; Soto-Mestre E; Pérez-Pérez MV; Figueroa-Baile N; Pérez LH; Rodríguez-Silva A; Martínez-Díaz E; Guillén-Nieto GE; Muzio-González VL
    Hum Vaccin; 2008; 4(1):54-9. PubMed ID: 18441530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
    Wong SL; Soosai P; Teoh YL; Han HH; Lefevre I; Bock HL
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):474-83. PubMed ID: 18564687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen.
    Bewley KM; Schwab JG; Ballanco GA; Daum RS
    Pediatrics; 1996 Nov; 98(5):898-904. PubMed ID: 8909483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation.
    Ahonkhai VI; Lukacs LJ; Jonas LC; Matthews H; Vella PP; Ellis RW; Staub JM; Dolan KT; Rusk CM; Calandra GB
    Pediatrics; 1990 Apr; 85(4 Pt 2):676-81. PubMed ID: 2107518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
    Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
    Gray BM
    Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-dependent V region expression in the human antibody response to the Haemophilus influenzae type b polysaccharide.
    Lucas AH; Azmi FH; Mink CM; Granoff DM
    J Immunol; 1993 Mar; 150(5):2056-61. PubMed ID: 8436834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in 2- to 6-month-old infants.
    Lenoir AA; Granoff PD; Granoff DM
    Pediatrics; 1987 Aug; 80(2):283-7. PubMed ID: 3112729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB).
    Vella PP; Staub JM; Armstrong J; Dolan KT; Rusk CM; Szymanski S; Greer WE; Marburg S; Kniskern PJ; Schofield TL
    Pediatrics; 1990 Apr; 85(4 Pt 2):668-75. PubMed ID: 2107517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L
    Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.